Volume 3, Issue 6

Clinical Decisions: Selecting the Right Disease Modifying Therapy

In this issue:

Selecting the most appropriate Disease Modifying Therapy (DMT) is becoming more complicated for patients with MS and clinicians who treat them. Newer approaches and newer agents are altering the benefit/risk equation, and making the question of which treatment is most appropriate for which patient more difficult to answer. 

That’s the focus of our discussion with Dr. Erin Longbrake, Assistant Professor of Neurology and Director of the Multiple Sclerosis Fellowship Program at Yale University, in this eMultipleSclerosis Review podcast. 

Learning objective:

  • Explain how the differences between the induction and escalation approaches to MS treatment can affect the choice of appropriate medications. 
  • Describe the safety and efficacy profiles of the newly approved oral MS therapies. 

Author:

Erin Longbrake, MD, PhD
Erin Longbrake, MD, PhD

Assistant Professor of Neurology 
Director, Multiple Sclerosis Fellowship Program  
Yale University 
New Haven, Connecticut

Program Directors:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: October 21, 2020
Expiration date: October 20, 2022